| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xiang-Ming Cai, Xiao-Yu Sun, Rui Li, Pei-Juan Wang, Jian-Cheng Qi, Yu-Xin Ge, Lei Yan. The hippocampal Salt-Inducible Kinase 2-CREB-Regulated Transcription Co-activator 1 system mediates the antidepressant actions of paroxetine in mice. Behavioural brain research. 2024-03-29. PMID:38552744. |
the hippocampal salt-inducible kinase 2 (sik2)-creb-regulated transcription co-activator 1 (crtc1) system has been demonstrated to participate in not only the pathogenesis of depression but also the antidepressant mechanisms of several antidepressant medications including fluoxetine, paroxetine, and mirtazapine. |
2024-03-29 |
2024-04-01 |
mouse |
| Magdalena Świądro-Piętoń, Dominika Dudek, Renata Wietecha-Posłuszn. Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338419. |
it has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. |
2024-02-10 |
2024-02-12 |
Not clear |
| Faruk Ugu. The Relationship Between Maternal Antidepressants and Neonatal Hypoglycemia: A Systematic Review. Alpha psychiatry. vol 22. issue 5. 2022-11-30. PMID:36447450. |
the searched keywords were as follows: antidepressants, pregnancy, selective serotonin reuptake inhibitors (ssris), citalopram, fluoxetine, paroxetine, escitalopram, sertraline, fluvoxamine, selective serotonin-norepinephrine reuptake inhibitors (snris), venlafaxine, tricyclic antidepressants (tcas), neonatal outcomes, neonatal hypoglycemia, imipramine, clomipramine, amitriptyline, bupropion, trazodone, and mirtazapine. |
2022-11-30 |
2023-08-14 |
Not clear |
| Amani J Basaeed, Gada Wafia, Bashair Alhidri, Layla A Sindi, Alqassem Y Hakami, Nisreen Jastania. The Prevalence of Atypical Antipsychotics, Antidepressants, and Benzodiazepines Use in Dementia Patients in King Abdulaziz Medical City. Cureus. vol 14. issue 10. 2022-11-21. PMID:36407231. |
for antidepressants, the most commonly prescribed medications for dementia were mirtazapine (62.5%), citalopram (45.8%), amitriptyline (8.3%), and paroxetine (4.2%). |
2022-11-21 |
2023-08-14 |
human |
| Martina Tallarico, Maria Pisano, Antonio Leo, Emilio Russo, Rita Citraro, Giovambattista De Sarr. Antidepressants drugs for seizures and epilepsy: Where do we stand? Current neuropharmacology. 2022-06-28. PMID:35761500. |
newer ads, such as selective serotonin reuptake inhibitors (srri) or serotonin-noradrenaline reuptake inhibitors (snri), particularly sertraline, citalopram, mirtazapine, reboxetine, paroxetine, fluoxetine, escitalopram, fluvoxamine, venlafaxine, duloxetine may lead to improvements in epilepsy severity instead the use of older tricyclic antidepressant (tcas) can increase the occurrence of seizures. |
2022-06-28 |
2023-08-14 |
Not clear |
| Masaki Kato, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Keiichiro Nishida, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshit. Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International journal of molecular sciences. vol 23. issue 7. 2022-04-12. PMID:35409234. |
this randomized control trial examined mirnas correlated with the early therapeutic effect of selective serotonin reuptake inhibitors (ssris; paroxetine or sertraline) and mirtazapine monotherapy. |
2022-04-12 |
2023-08-13 |
human |
| Le Xiao, Xuequan Zhu, Amy Gillespie, Yuan Feng, Jingjing Zhou, Xu Chen, Yuanyuan Gao, Xueyi Wang, Xiancang Ma, Chengge Gao, Yunshi Xie, Xiaoping Pan, Yan Bai, Xiufeng Xu, Gang Wang, Runsen Che. Effectiveness of mirtazapine as add-on to paroxetine Psychological medicine. vol 51. issue 7. 2021-11-30. PMID:31931894. |
effectiveness of mirtazapine as add-on to paroxetine this study aimed to examine the efficacy of combining paroxetine and mirtazapine v. switching to mirtazapine, for patients with major depressive disorder (mdd) who have had an insufficient response to ssri monotherapy (paroxetine) after the first 2 weeks of treatment. |
2021-11-30 |
2023-08-13 |
Not clear |
| Rui Lopes, José Carlos Alves, Raquel Garcia Reg. Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants. Case reports in medicine. vol 2016. 2020-10-01. PMID:27807450. |
trazodone addition to paroxetine and mirtazapine in a patient with treatment-resistant depression: the pros and cons of combining three antidepressants. |
2020-10-01 |
2023-08-13 |
Not clear |
| Rui Lopes, José Carlos Alves, Raquel Garcia Reg. Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants. Case reports in medicine. vol 2016. 2020-10-01. PMID:27807450. |
we report a relapse of moderate-to-severe depressive symptoms with insomnia that successfully remitted after the addition of trazodone to a dual combination of paroxetine and mirtazapine (in standard effective doses) in a patient with treatment-resistant depression. |
2020-10-01 |
2023-08-13 |
Not clear |
| Shrutakirthi D Shenoi, Savitha Soman, Ravindra Munoli, Smitha Prabh. Update on Pharmacotherapy in Psychodermatological Disorders. Indian dermatology online journal. vol 11. issue 3. 2020-09-28. PMID:32695685. |
the commonly used antidepressants in dermatology include selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), selective serotonin norepinephrine reuptake inhibitors (venlafaxine, desvenlefaxine, and duloxetine), norepinephrine dopamine reuptake inhibitors (bupropion), tricyclic antidepressants (doxepin, amitriptyline, imipramine, and clomipramine), and tetracyclic antidepressants (mirtazapine). |
2020-09-28 |
2023-08-13 |
Not clear |
| Junichi Mukai, Saki Maruyama, Katsuya Otori, Rie Kubot. [Antidepressant Medication Use and Development of Hyperglycemia and Diabetes Mellitus: A Japanese Adverse Drug Event Report Database Study]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 140. issue 4. 2020-09-07. PMID:32238642. |
the lower limit of 95%ci of rors for 13 antidepressants (imipramine, clomipramine, nortriptyline, amitriptyline, amoxapine, maprotiline, mianserin, sertraline, paroxetine, escitalopram, duloxetine, mirtazapine, and trazodone), which included all subclasses, exceeded 1. |
2020-09-07 |
2023-08-13 |
Not clear |
| b' Jaroslava \\xc4\\x8cerve\\xc5\\x88ov\\xc3\\xa. Combination of mirtazapine and paroxetine: possible clinically demonstrated interaction? Casopis lekaru ceskych. vol 158. issue 7-8. 2020-02-03. PMID:31995999.' |
the case report describes a case of a patient who reported significant depression after adding paroxetine and mirtazapine to psychiatric medication. |
2020-02-03 |
2023-08-13 |
Not clear |
| Sophie Billioti de Gage, Cédric Collin, Thien Le-Tri, Antoine Pariente, Bernard Bégaud, Hélène Verdoux, Rosemary Dray-Spira, Mahmoud Zurei. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS drugs. vol 32. issue 7. 2019-10-10. PMID:29959758. |
nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake inhibitors (snris: venlafaxine, milnacipran, duloxetine) and 'other antidepressants' (mianserin, mirtazapine, tianeptine and agomelatine), particularly in comparison with selective serotonin reuptake inhibitors (ssris: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram), which are by far the most commonly prescribed antidepressants. |
2019-10-10 |
2023-08-13 |
Not clear |
| Natalia Górska, Jakub Słupski, Wiesław Jerzy Cubała, Mariusz Stanisław Wiglusz, Maria Gałuszko-Węgielni. Antidepressants in epilepsy. Neurologia i neurochirurgia polska. vol 52. issue 6. 2019-06-06. PMID:30131174. |
clinicians applying first line of depression treatment in patients with epilepsy should consider use of ssris or snris, particularly sertraline, citalopram, mirtazapine, reboxetine, paroxetine, fluoxetine, escitalopram, fluvoxamine, venlafaxine, duloxetine. |
2019-06-06 |
2023-08-13 |
Not clear |
| Katerina Grabicova, Roman Grabic, Ganna Fedorova, Jerker Fick, Daniel Cerveny, Jitka Kolarova, Jan Turek, Vladimir Zlabek, Tomas Randa. Bioaccumulation of psychoactive pharmaceuticals in fish in an effluent dominated stream. Water research. vol 124. 2017-10-20. PMID:28825984. |
bioaccumulation of 11 selected psychoactive pharmaceuticals (citalopram, clomipramine, haloperidol, hydroxyzine, levomepromazine, mianserin, mirtazapine, paroxetine, sertraline, tramadol and venlafaxine) was examined in zivny stream (tributary of the blanice river, the czech republic), which is a small stream highly affected by effluent from the prachatice stp. |
2017-10-20 |
2023-08-13 |
Not clear |
| Jacek C Szepietowski, Radomir Reszk. Psychogenic Itch Management. Current problems in dermatology. vol 50. 2017-04-18. PMID:27578081. |
as in pruritus of other causes, several drugs are used, with more emphasis on substances that influence central nervous system: h1-antihistamines (hydroxyzine, chlorpheniramine, cyproheptadine, diphenhydramine, promethazine), tricyclic antidepressants (doxepin), tetracyclic antidepressants (mirtazapine), selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), antipsychotic drugs (pimozide), anticonvulsants (topiramate), and benzodiazepines (alprazolam), preferably depending on the coexisting symptoms. |
2017-04-18 |
2023-08-13 |
Not clear |
| Go Taniguchi, Miho Miyajima, Masako Watanabe, Yoshiko Murata, Daichi Sone, Yutaka Watanabe, Mitsutoshi Okazaki, Motonori Kobayashi-Kimura, Masaaki Kato, Teiichi Onum. Nonconvulsive status epilepticus in the elderly associated with newer antidepressants used at therapeutic doses: A report of three cases. Epilepsy & behavior case reports. vol 3. 2015-03-04. PMID:25737963. |
after titrating to therapeutic doses (paroxetine 20 mg/day, sertraline 50 mg/day, and combination of sertraline 50 mg/day and mirtazapine 30 mg/day in one patient each), impaired consciousness appeared. |
2015-03-04 |
2023-08-13 |
Not clear |
| Tamaki Ishima, Yuko Fujita, Kenji Hashimot. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. European journal of pharmacology. vol 727. 2015-01-29. PMID:24508523. |
first, we examined the effects of selective serotonin reuptake inhibitors (ssris) (fluvoxamine, paroxetine, sertraline, citalopram and escitalopram), serotonin and noradrenaline reuptake inhibitors (snris) (duloxetine, venlafaxine, milnacipran), and mirtazapine, a noradrenaline and specific serotonergic antidepressant (nassa), on [(3)h](+)-pentazocine binding to rat brain membranes. |
2015-01-29 |
2023-08-12 |
rat |
| F Montañés-Rada, M T De Lucas-Taracena, S Sánchez-Romer. Mirtazapine versus paroxetine in panic disorder: an open study. International journal of psychiatry in clinical practice. vol 9. issue 2. 2014-06-17. PMID:24930788. |
mirtazapine versus paroxetine in panic disorder: an open study. |
2014-06-17 |
2023-08-13 |
Not clear |
| F Montañés-Rada, M T De Lucas-Taracena, S Sánchez-Romer. Mirtazapine versus paroxetine in panic disorder: an open study. International journal of psychiatry in clinical practice. vol 9. issue 2. 2014-06-17. PMID:24930788. |
we designed an open study that evaluates changes induced by mirtazapine compared with paroxetine in panic disorder. |
2014-06-17 |
2023-08-13 |
Not clear |